H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on the shares following the Q4 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs
- Revolution Medicines Reports 2024 Financial Results and Progress
- Revolution Medicines reports Q4 EPS ($1.12), consensus (96c)
- Revolution Medicines sees FY25 GAAP net loss $840M-$900M
- RVMD Upcoming Earnings Report: What to Expect?